Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
I. Pascual Castroviejo.
Neurofibromatosis.
pp. 73-78
[2.]
B.J. Maron.
Hypertrophic cardiomyopathy.
Lancet, 350 (1997), pp. 127-133
[3.]
B.J. Maron, W.K. Shen, S. Link M, A.E. Epstein, A.K. Almquist, J.P. Dau-bert, et al.
Efficacy of implantable cardioverterdefibrillators for the prevention of sudden death in patients with hypertrophic cardiomyopathy.
N Engl J Med, 342 (2000), pp. 365-373
[4.]
A.E. Lin, P.H. Birch, B.R. Korf, R. Tenconi, M. Niimura, M. Poyhonen, et al.
Cardiovascular malformations and other cardiovascular abnormalities in Neurofibromatosis 1.
Am J Med Genet, 95 (2000), pp. 108-117
[5.]
A.P. Fitzpatrick, R.W. Emanuel.
Familial neurofibromatosis and hypertrophic cardiomyopathy.
Br Heart, 60 (1988), pp. 247-251
[6.]
M.A. Tedesco, G. Di Salvo, F. Natale, V. Pergola, E. Calabrese, C. Grassia, et al.
The heart in neurofibromatosis type 1: An echocardiographic study.
Am Heart J, 143 (2002), pp. 883-888
[7.]
National Institutes of Health Consensus Development Confe-rence.
Neurofibromatosis conference statement.
Arch Neurol, 45 (1988), pp. 575-578
[8.]
M.G. St John Sutton, A.J. Tajik, E.R. Giuliani, H. Gordon, W.P.D. Su.
Hypertrophic obstructive cardiomyopathy and lentiginosis: A little known neural ectodermal syndrome.
Am J Cardiol, 47 (1981), pp. 214-218
[9.]
D.H. Gutmann, R.T. Geist, K. Rose, D.E. Wright.
Expression of two new protein isoforms of the neurofibromatosis type 1 gene product, neurofibromin, in muscle tissues.
Dev Dyn, 202 (1995), pp. 302-311
Copyright © 2004. Asociación Española de Pediatría
